Mostafa Salama

Dr. Mostafa Salama


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in Children
Verified
Journal Article
Open access
PDF file
MSMostafa Salama
Mostafa Salama
DHDoha Hassan
Doha Hassan
Seema KumarSeema Kumar
Seema Kumar
Childhood obesity has assumed epidemic proportions; it results from a complex interplay of genetic, physiological, socioeconomic, and environmental factors. It is associated with numerous short- and long-term health complications, including cardiometabolic and psychosocial consequences. While lifestyle modifications remain the cornerstone of treatment, their overall impact is modest. As a result, pharmacotherapy is increasingly recommended as an adjunct in selected pediatric patients, particularly those with severe or refractory obesity. In recent years, several anti-obesity medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, have shown promise in pediatric populations, particularly adolescents. However, the pharmacologic options remain limited for younger children. This review summarizes current evidence on the efficacy and safety of available anti-obesity medications in children and adolescents, offering practical, age-based strategies to guide the appropriate clinical use of these medications as part of a comprehensive obesity-management plan.

15 May 2025 in Pediatric Obesity
Verified
Journal Article
Closed access
MSMostafa Salama
Mostafa Salama
KLKaitlin Leopold
Kaitlin Leopold
RHRoland Hentz
Roland Hentz
Seema KumarSeema Kumar
Seema Kumar

25 July 2024 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
MSMostafa Salama
Mostafa Salama
Filippo VairoFilippo Vairo
Filippo Vairo
RHRoland Hentz
Roland Hentz
ANAlaa Al Nofal
Alaa Al Nofal
SHSara Hassan
Sara Hassan
Seema KumarSeema Kumar
Seema Kumar
Context Variants in melanocortin 4 receptor (MC4R) pathway-related genes have been associated with obesity. The association of these variants with cardiometabolic parameters are not fully known. Objective We compared the severity of obesity and cardiometabolic risk markers in children with MC4R pathway-related clinically reported genetic variants relative to children without these variants. Methods A retrospective chart review was performed in children with obesity who underwent multigene panel testing for monogenic obesity. Results Data on a total of 104 children were examined, with 93 (89%) identified as White. Thirty-nine (37.5%) patients had clinically reported variants in the MC4R pathway, and the remaining 65 patients did not have reported MC4R pathway-related variants. Among the MC4R-related variants, PCSK1 risk alleles were most common, reported in 15 children (14%). The maximum body mass index percent of the 95th percentile was not different between groups (P = .116). Low-density lipoprotein cholesterol (LDL-C) was not different between groups (P = .132). However, subgroup analysis demonstrated higher LDL cholesterol in children with the PCSK1 c.661A>G risk allele relative to those with MC4R-related variant of uncertain significance (P = .047), negative genetic testing (P = .012), and those with non-MC4R related variants (P = .048). The blood pressure, fasting glucose, hemoglobin A1C, total cholesterol, alanine transaminase, and high-density lipoprotein cholesterol were not different between groups. Conclusion Variants in the MC4R pathway-related genes were not associated with severity of obesity and cardiometabolic risk markers except for the c.661A>G PCSK1 risk allele, which was associated with higher LDL-C levels.

11 November 2025 in Journal of the Endocrine Society
Verified
Journal Article
Open access
MSMostafa Salama
Mostafa Salama
DHDoha Hassan
Doha Hassan
SPSiobhan Pittock
Siobhan Pittock
ALAida Lteif
Aida Lteif
Seema KumarSeema Kumar
Seema Kumar
Context: Pharmacological options for the treatment of early severe childhood obesity are limited. Objective: This retrospective case series evaluates the effect of topiramate on weight and cardiometabolic parameters in young children with severe obesity, including those with hypothalamic etiologies. Methods: This is a retrospective case series including 14 children with severe obesity, who were treated with topiramate prior to age 12 years. Anthropometric and metabolic data were analyzed. Results: The median age at initiation of topiramate treatment was 10.1 years (range, 7.9-11.2 years) and 64% were boys. At baseline, the median body mass index (BMI) was 149% of the 95th percentile (range, 136%-200%). The median treatment duration was 14 months (interquartile range, 9.5-24 months), with a maximum tolerated dose of 75 mg (range, 50-150 mg). There was a median decrease in BMI% of the 95th percentile of 8% (95% CI, −15 to −1.02; P = .042), and a reduction in BMI z score by 0.37 (95% CI, −0.66 to −0.05; P = .028). The most notable response was in a child with hypothalamic obesity who experienced a 35-point reduction in BMI% of the 95th percentile over 24 months. While 11 of 14 children showed reduction in BMI, 3 had no change or increase in their BMI. No significant changes were observed in cardiometabolic markers or linear growth. Conclusion: Topiramate monotherapy resulted in significant BMI reductions in young children with severe obesity, including those with hypothalamic obesity. Further prospective randomized controlled trials are warranted to assess its long-term efficacy for obesity management in young children.

10 February 2026 in Pediatric Obesity
Verified
Journal Article
Closed access
MSMostafa Salama
Mostafa Salama
DHDoha Hassan
Doha Hassan
FVFilippo Pinto e Vairo
Filippo Pinto e Vairo
ALAida Lteif
Aida Lteif
RHRoland Hentz
Roland Hentz
Seema KumarSeema Kumar
Seema Kumar

2 March 2026 in Epidemiologia
Verified
Journal Article
Open access
PDF file
DHDoha Hassan
Doha Hassan
MSMostafa Salama
Mostafa Salama
RAReham Ahmed
Reham Ahmed
Seema KumarSeema Kumar
Seema Kumar
Pediatric obesity represents an urgent public health concern, with rapidly increasing prevalence across all regions. While genetic susceptibility contributes significantly to interindividual variability in weight, the significant increase in obesity prevalence over the last 30 years is driven by shifts in environmental contributors. This narrative review will summarize evidence on the major environmental determinants of childhood obesity. Environmental contributors to obesity include the food environment, physical activity and built environments, socioeconomic and community context, home and family environments, digital exposures, early life and chemical obesogens and policy drivers. These environmental factors influence activity patterns, dietary habits, sleep, and stress. Additionally, many of these contributing factors cluster within communities that are disadvantaged, thereby increasing predisposition of specific racial, ethnic and socioeconomic groups to childhood obesity. We highlight research gaps and opportunities for multisectoral interventions aligned to impact the growing prevalence of childhood obesity.